Loading...
•
Dec 31, 2020
10X Genomics Q4 2020 Earnings Report
Reported a 49% increase in revenue compared to the same quarter last year.
Key Takeaways
10x Genomics reported a revenue of $112.2 million for Q4 2020, a 49% increase compared to Q4 2019. The company's gross margin was 83%, up from 78% in the prior year period. However, the company experienced a significant operating loss of $409.6 million, driven by a large increase in operating expenses due to in-process research and development expenses related to the ReadCoor acquisition.
Revenue for Q4 2020 was $112.2 million, representing a 49% increase year-over-year.
Gross margin for Q4 2020 was 83%, compared to 78% in Q4 2019.
Operating loss for Q4 2020 was $409.6 million, compared to an operating loss of $8.1 million for the same period last year.
Net loss for Q4 2020 was $415.6 million, compared to a net loss of $7.1 million for the corresponding prior year period.
Forward Guidance
10x Genomics expects full year 2021 revenue to be in the range of $480 million to $500 million, representing 61% to 67% growth over full year 2020 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...